APM Stock - Aptorum Group Limited
Unlock GoAI Insights for APM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $431,378 | $1.30M | $1.54M | $911,509 |
| Gross Profit | $-255,000 | $10,566 | $80,065 | $81,854 | $-104,000 |
| Gross Margin | N/A | 2.4% | 6.2% | 5.3% | -11.4% |
| Operating Income | $-3,796,000 | $-10,601,000 | $-17,509,113 | $-19,207,000 | $-19,894,900 |
| Net Income | $-4,268,000 | $-2,825,000 | $-9,800,000 | $-25,048,000 | $7.07M |
| Net Margin | N/A | -654.9% | -756.2% | -1624.4% | 775.3% |
| EPS | $-0.78 | $-0.62 | $-2.75 | $-7.15 | $2.03 |
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Visit WebsiteEarnings History & Surprises
APMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q4 2025 | Oct 3, 2025 | — | — | — | — |
Q2 2025 | Apr 28, 2025 | — | $-0.29 | — | — |
Q4 2024 | Dec 20, 2024 | — | $-0.50 | — | — |
Q2 2024 | Apr 30, 2024 | $-2.70 | $0.51 | +119.0% | ✓ BEAT |
Q4 2023 | Dec 22, 2023 | $-2.60 | $-1.43 | +45.2% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $-2.60 | $-2.22 | +14.8% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-3.00 | $-0.53 | +82.4% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $-3.30 | $-2.52 | +23.8% | ✓ BEAT |
Q4 2021 | Dec 3, 2021 | $-3.00 | $-4.69 | -56.4% | ✗ MISS |
Q2 2021 | Apr 19, 2021 | $-3.10 | $3.90 | +225.8% | ✓ BEAT |
Q3 2020 | Sep 1, 2020 | $-2.50 | $-2.07 | +17.2% | ✓ BEAT |
Q2 2020 | Apr 29, 2020 | — | $-3.31 | — | — |
Q3 2019 | Sep 9, 2019 | — | $-3.14 | — | — |
Q2 2019 | Apr 15, 2019 | — | $-5.31 | — | — |
Q4 2018 | Dec 4, 2018 | — | $-1.89 | — | — |
Latest News
DiamiR To Highlight Potential Of Brain-Enriched, Inflammation-Associated microRNAs As Epigenetic Biomarkers Of Neurodegeneration At CTAD Conference
📈 PositiveAptorum Group Announces $2M Registered Direct Offering Of 1M Shares At $2 Each, Plus $4M Upside From 2M Unregistered Warrants In Concurrent Private Placement
➖ NeutralAptorum shares are trading lower, pulling back after surging on Thursday.
➖ NeutralAptorum Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 141.73%
📈 PositiveAptorum Group shares are trading higher after the company announced that New York State's Department of Health has approved the DiamiR APOE genotyping test.
📈 PositiveMarket-Moving News for August 21st
➖ NeutralDiamiR's APOE Genotyping Test Receives CLEP Approval From New York State Department Of Health
📈 PositiveAptorum Group regains compliance with Nasdaq's minimum bid price rule
📈 PositiveFrequently Asked Questions about APM
What is APM's current stock price?
What is the analyst price target for APM?
What sector is Aptorum Group Limited in?
What is APM's market cap?
Does APM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to APM for comparison